Boston Scientific Gives Up On Lotus Edge TAVR

 
• By Reed Miller

The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.

Hand holding scissors to cut banknotes
• Source: shutterstock.com

More from Strategy

More from Business